File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Immune-related Endocrine Dysfunction in Chinese: a single tertiary centre experience

TitleImmune-related Endocrine Dysfunction in Chinese: a single tertiary centre experience
Authors
Issue Date2020
PublisherElsevier BV. The Journal's web site is located at https://www.journals.elsevier.com/annals-of-oncology
Citation
European Society for Medical Oncology (ESMO) Virtual Congress 2020, 19–21 September / 16–18 October 2020. In Annals of Oncology, 2020, v. 31 n. Suppl. 4, p. S1060, abstract no. 1850P How to Cite?
AbstractBackground: Cancer immunotherapy, particularly treatment with immune checkpoint inhibitors, has become an important treatment of many cancer types. Use of immune checkpoint inhibitors is often associated with immune-related adverse events (irAEs). Endocrine dysfunction is one of the common irAEs. Majority of the studies on immune-related endocrine dysfunction (irED) were conducted in Western countries and there is few Asian patients data. This study aims to review the frequency and nature of irED in Chinese. Methods: A retrospective review of all Chinese patients treated for cancer with antiPD1/ anti-PDL1 or anti-CTLA4 or combination therapy (with chemotherapy or targeted agent) in Department of Clinical Oncology, Queen Mary Hospital, from January 2014 to December 2019 was performed. Demographic data, cancer type and stage, drug treatment, details about irEDs were extracted. Results: Total 953 patients (male: 603, 64%; median age: 62.0 years) received immune checkpoint inhibitors during the study period. 570 patients (59.8%) used monoimmunotherapy, 133 (14.0%) used dual-immunotherapy, 206 (21.6%) used immunotherapy with chemotherapy and 78 (8.2%) used immunotherapy with targeted agent. 168 patients (17.63%) had hypothyroidism with median onset time 9.9+/-17.5 weeks. 71 patients (11.8%) had hyperthyroidism with median onset time 8.1+/-25.3 weeks. 82 patients (8.6%) had hypocortisolism with median onset time 21.2+/-26.6 weeks. 69 patients (7.2%) had hypercortisolium with median onset time 9.6+/-33.1 weeks.
Persistent Identifierhttp://hdl.handle.net/10722/287793
ISSN
2019 Impact Factor: 18.274
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorChan, WLW-
dc.contributor.authorHo, P-
dc.contributor.authorLeung, KH-
dc.contributor.authorLau, KS-
dc.contributor.authorAu, J-
dc.contributor.authorLam, V-
dc.contributor.authorHo, I-
dc.contributor.authorCheung, B-
dc.contributor.authorLam, E-
dc.contributor.authorWong, C-
dc.contributor.authorLiu, R-
dc.contributor.authorTse, R-
dc.contributor.authorChow, D-
dc.contributor.authorTse, T-
dc.contributor.authorLam, KO-
dc.contributor.authorLee, VHF-
dc.contributor.authorChoi, CW-
dc.date.accessioned2020-10-05T12:03:22Z-
dc.date.available2020-10-05T12:03:22Z-
dc.date.issued2020-
dc.identifier.citationEuropean Society for Medical Oncology (ESMO) Virtual Congress 2020, 19–21 September / 16–18 October 2020. In Annals of Oncology, 2020, v. 31 n. Suppl. 4, p. S1060, abstract no. 1850P-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/287793-
dc.description.abstractBackground: Cancer immunotherapy, particularly treatment with immune checkpoint inhibitors, has become an important treatment of many cancer types. Use of immune checkpoint inhibitors is often associated with immune-related adverse events (irAEs). Endocrine dysfunction is one of the common irAEs. Majority of the studies on immune-related endocrine dysfunction (irED) were conducted in Western countries and there is few Asian patients data. This study aims to review the frequency and nature of irED in Chinese. Methods: A retrospective review of all Chinese patients treated for cancer with antiPD1/ anti-PDL1 or anti-CTLA4 or combination therapy (with chemotherapy or targeted agent) in Department of Clinical Oncology, Queen Mary Hospital, from January 2014 to December 2019 was performed. Demographic data, cancer type and stage, drug treatment, details about irEDs were extracted. Results: Total 953 patients (male: 603, 64%; median age: 62.0 years) received immune checkpoint inhibitors during the study period. 570 patients (59.8%) used monoimmunotherapy, 133 (14.0%) used dual-immunotherapy, 206 (21.6%) used immunotherapy with chemotherapy and 78 (8.2%) used immunotherapy with targeted agent. 168 patients (17.63%) had hypothyroidism with median onset time 9.9+/-17.5 weeks. 71 patients (11.8%) had hyperthyroidism with median onset time 8.1+/-25.3 weeks. 82 patients (8.6%) had hypocortisolism with median onset time 21.2+/-26.6 weeks. 69 patients (7.2%) had hypercortisolium with median onset time 9.6+/-33.1 weeks.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at https://www.journals.elsevier.com/annals-of-oncology-
dc.relation.ispartofAnnals of Oncology-
dc.relation.ispartofEuropean Society for Medical Oncology (ESMO) Virtual Congress, 2020-
dc.titleImmune-related Endocrine Dysfunction in Chinese: a single tertiary centre experience-
dc.typeConference_Paper-
dc.identifier.emailChan, WLW: winglok@hku.hk-
dc.identifier.emailLeung, KH: oscarlkh@hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailChoi, CW: hcchoi@hku.hk-
dc.identifier.authorityChan, WLW=rp02541-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityLee, VHF=rp00264-
dc.description.natureabstract-
dc.identifier.doi10.1016/j.annonc.2020.08.1497-
dc.identifier.hkuros314758-
dc.identifier.volume31-
dc.identifier.issueSuppl. 4-
dc.identifier.spageS1060, abstract no. 1850P-
dc.identifier.epageS1060, abstract no. 1850P-
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats